King Luther Capital Management Corp Decreases Holdings in Charles River Laboratories International, Inc. (CRL)

King Luther Capital Management Corp lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 7.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 90,813 shares of the medical research company’s stock after selling 7,175 shares during the period. King Luther Capital Management Corp owned 0.19% of Charles River Laboratories International worth $9,810,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in CRL. Great West Life Assurance Co. Can lifted its stake in shares of Charles River Laboratories International by 0.7% in the 2nd quarter. Great West Life Assurance Co. Can now owns 40,296 shares of the medical research company’s stock valued at $4,071,000 after purchasing an additional 271 shares during the last quarter. World Asset Management Inc lifted its stake in shares of Charles River Laboratories International by 2.2% in the 2nd quarter. World Asset Management Inc now owns 2,762 shares of the medical research company’s stock valued at $279,000 after purchasing an additional 59 shares during the last quarter. Sei Investments Co. lifted its stake in shares of Charles River Laboratories International by 12.7% in the 2nd quarter. Sei Investments Co. now owns 110,465 shares of the medical research company’s stock valued at $11,174,000 after purchasing an additional 12,424 shares during the last quarter. Retirement Systems of Alabama lifted its stake in shares of Charles River Laboratories International by 0.3% in the 2nd quarter. Retirement Systems of Alabama now owns 88,915 shares of the medical research company’s stock valued at $8,994,000 after purchasing an additional 255 shares during the last quarter. Finally, Advisor Partners LLC acquired a new position in Charles River Laboratories International during the 2nd quarter worth $208,000. 96.27% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have weighed in on the stock. Zacks Investment Research raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 target price for the company in a research report on Tuesday, October 24th. Credit Suisse Group reissued a “neutral” rating and set a $112.00 target price (up previously from $95.00) on shares of Charles River Laboratories International in a research report on Monday, October 16th. Jefferies Group boosted their target price on shares of Charles River Laboratories International from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Robert W. Baird reissued a “buy” rating and set a $114.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 1st. Finally, Royal Bank Of Canada initiated coverage on shares of Charles River Laboratories International in a report on Tuesday, September 19th. They set a “sector perform” rating and a $110.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Charles River Laboratories International currently has a consensus rating of “Buy” and a consensus price target of $106.63.

In related news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $0.27, for a total value of $270,000.00. Also, insider Davide Molho sold 6,165 shares of the company’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $110.00, for a total transaction of $678,150.00. The disclosure for this sale can be found here. In the last three months, insiders purchased 10,500 shares of company stock worth $2,885. 2.20% of the stock is currently owned by insiders.

Charles River Laboratories International, Inc. (NYSE:CRL) opened at $101.82 on Wednesday. Charles River Laboratories International, Inc. has a twelve month low of $71.48 and a twelve month high of $119.05. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13. The stock has a market cap of $4,834.19, a PE ratio of 20.05, a PEG ratio of 1.63 and a beta of 0.89.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.22 by $0.08. The business had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 earnings per share. equities research analysts forecast that Charles River Laboratories International, Inc. will post 5.13 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “King Luther Capital Management Corp Decreases Holdings in Charles River Laboratories International, Inc. (CRL)” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/12/06/king-luther-capital-management-corp-decreases-holdings-in-charles-river-laboratories-international-inc-crl.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

What are top analysts saying about Charles River Laboratories International Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Charles River Laboratories International Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit